Pohl, M <br/><br/>
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.  [electronic resource] 

 -  Zeitschrift fur Gastroenterologie  Oct 2011 
 - 1398-406 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1439-7803 
<br/><br/><label>Standard No.: </label>10.1055/s-0031-1281752  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>AC133 Antigen<br/>Aged<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antigens, CD--blood<br/>Antigens, CD34--blood<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Biomarkers--blood<br/>Cell Count<br/>Colorectal Neoplasms--blood supply<br/>Disease Progression<br/>Endothelial Cells--drug effects<br/>Endothelium, Vascular--drug effects<br/>Female<br/>Flow Cytometry<br/>Glycoproteins--blood<br/>Humans<br/>Immunohistochemistry<br/>Male<br/>Middle Aged<br/>Peptides--blood<br/>Pilot Projects<br/>Stem Cells--drug effects<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Vascular Endothelial Growth Factor Receptor-2--blood